In the multicentre , placebo-controlled , double-blind REPAIR-AMI trial , 204 patients received intracoronary infusion of BMCs ( n = 101 ) or placebo ( n = 103 ) into the infarct vessel 3-7 days following successful percutaneous coronary intervention .